AATS: American Association for Thoracic Surgery.
Watch the AATS Leadership Video
 
Tracheal Sleeve Pneumonectomy for Lung Cancer After Induction Chemotherapy
Domenico Galetta, Piergiorgio Solli, Giulia Veronesi, Alessandro Borri, Roberto Gasparri, Francesco Petrella, Lorenzo Spaggiari; Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy

Objective: Non-small cell lung cancer (NSCLC) less than 2 cm from the carina or invading the tracheo-bronchial angle, formerly considered inoperable, may be amenable to an “extended” resection (tracheal sleeve pneumonectomy - TSP). In these patients the role of induction chemotherapy (IC) and their effects on morbidity and mortality are unclear. We evaluated the surgical results and the long-term outcome of patients who underwent TSP for locally advanced NSCLC after IC.
Methods: From September 1998 to September 2008, 29 patients (19 men; median age of 58 years) with NSCLC of the carinal or tracheo-bronchial angle received induction chemotherapy (cisplatin based polichemotherapy) after mediastinoscopy. Patients with disease judged to be resectable at restaging underwent surgery.
Results: All patients were available for re-staging. No complete response was observed. Twelve patients (41.4%) had a progression disease. Partial response rate was 41.4% (n=12), and stable disease 17.2% (n=5). All patient with partial response and stable disease (n=17, all with pN2) underwent surgery. Superior vena cava was involved and resected in 11 cases (64.7%). Complete resection was achieved in 14 patients (82.3%). Thirty-day mortality was 5.8% (n=1). Major complications occurred in 4 patients (23.5%): 3 bronchopleural fistulas (17.6%), 2 ARDS (11.7%), and 1 cardiac hernia (5.8%). Nodal downstaging was diagnosed in 9 (53%) patients (all passed from N2 to N1). Median survival was 12 months (range, 1 to 90 months). Overall 5-year survival rate was 34%. Overall, 5-year freedom from recurrence was 58.2%. Seven patients (41%) had recurrence: 1 local (5.8%) and 6 systemic (35.2%). Patients receiving postoperative radiotherapy (n=8) and those with downstaging had a significant 5-year survival rate (50.6% vs 0%; logrank, p= .007, and 63.5% vs 0%; log-rank, p = .04). Patients with squamous cell carcinoma (n=9) had a best prognosis in respect of those with adenocarcinoma (n=8) (76.2% vs 0%; logrank, p=.002). At multivariate analysis, postoperative radiotherapy influenced long-term survival (p=.04).
Conclusion: Induction chemotherapy improves patient selection avoiding useless operation allowing a safety TSP with acceptable morbidity and mortality. In or experience, downstaging and squamous cell carcinoma are associated to a best prognosis. Postoperative radiotherapy improves long-term survival.
Back to 2009 Annual Meeting
Back to Program Outline
Back to Main Program
We Model Excellence
Follow AATS on Facebook
Copyright © American Association for Thoracic Surgery. All rights reserved.
Read the Privacy Policy.
IMPORTANT REMINDER: The preceding information is intended only to provide
general guidance and not as a definitive basis for diagnosis or treatment in any particular case.
It is very important that you consult a doctor about any specific medical problem or question.